• Product NameTG101209
• Brief DescriptionInhibitors
• Purification99.50%
• Biological ActivityTG101209 is a selective JAK2 inhibitor with IC50 of 6 nM, less potent to Flt3 and RET with IC50 of 25 nM and 17 nM in cell-free assays, ~30-fold selective for JAK2 than JAK3, sensitive to JAK2V617F and MPLW515L/K mutations.
• Target Namec-RET inhibitor; FLT inhibitor; JAK inhibitor
• CAS No. 936091-14-4
• Calculated MW 509.67
• Formulation C26H35N7O2S
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:CN1CCN(CC1)C1=CC=C(NC2=NC=C(C)C(NC3=CC(=CC=C3)S(=O)(=O)NC(C)(C)C)=N2)C=C1
  Pathways:Angiogenesis; Apoptosis; Chromatin/Epigenetic; Tyrosine Kinase/Adaptors; JAK/STAT signaling; Stem Cells
  Receptor:RET; FLT3; JAK2; JAK3
  Boling pt:
  Melting pt:
  Solubility:DMSO: 102 mg/mL (200.12 mM)
  Appearance:White Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Pardanani A, et al, Leukemia, 2007, 21(8), 1658-1668.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting